Neurocrine Biosciences, Inc. today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational compound ...
SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine ...
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating ...
Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with ...
We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...
In a report released today, Laura Chico from Wedbush maintained a Buy rating on Tourmaline Bio (TRML – Research Report), with a price target of ...
M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth ...
SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18 ...
SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback